Proteostasis To Present At Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), today announced that Meenu Chhabra, president and chief executive officer of Proteostasis Therapeutics, will present at the following upcoming investor conferences:

  • Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series on Wednesday, September 28, 2016 at 2:05 p.m. ET in New York City.
  • Jefferies Cystic Fibrosis Summit on Thursday, September 29, 2016 at 8:45 a.m. ET in New York City.

A live audio webcast of the Leerink Partners presentation will be available on the Event Calendar page in the Investors & Media section of the Company’s website, A replay of the webcast will be available on the Company’s website following the presentation.

About Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery of groundbreaking therapies to treat diseases caused by dysfunctional protein processing, such as cystic fibrosis (CF). Headquartered in Cambridge, MA, the Proteostasis Therapeutics team focuses on identifying therapies that modulate the proteostasis imbalance in cells and restore protein function. Proteostasis Therapeutics is currently enrolling eligible adults with CF to participate in its Phase 1 clinical trials of PTI-428. PTI-428 is a unique modulator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, called an amplifier, that when used in combination with existing treatments and therapies has shown a consistent positive effect on CFTR protein activity in vitro in pre-clinical studies. In addition to its multiple programs in cystic fibrosis, Proteostasis Therapeutics has formed collaborations with Biogen to research and identify therapeutic candidates for neurodegenerative disease and with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. For more information, visit

Media Contact:
Katie Engleman, Pure Communications, Inc.
(910) 509-3977

Investor Contact:
Luke Heagle, Pure Communications, Inc.
(910) 726-1372

Back to news